INFI Annual EBITDA
-$43.73 M
+$871.00 K+1.95%
31 December 2022
Summary:
As of January 21, 2025, INFI annual earnings before interest, taxes, depreciation & amortization is -$43.73 million, with the most recent change of +$871.00 thousand (+1.95%) on December 31, 2022. During the last 3 years, it has risen by +$598.00 thousand (+1.35%).INFI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI Quarterly EBITDA
-$9.80 M
+$1.09 M+10.00%
30 June 2023
Summary:
As of January 21, 2025, INFI quarterly earnings before interest, taxes, depreciation & amortization is -$9.80 million, with the most recent change of +$1.09 million (+10.00%) on June 30, 2023. Over the past year, it has increased by +$2.02 million (+17.05%).INFI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI TTM EBITDA
-$40.34 M
+$2.02 M+4.76%
30 June 2023
Summary:
As of January 21, 2025, INFI TTM earnings before interest, taxes, depreciation & amortization is -$40.34 million, with the most recent change of +$2.02 million (+4.76%) on June 30, 2023. Over the past year, it has increased by +$5.78 million (+12.54%).INFI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +1.9% | +17.1% | +12.5% |
| 3 y3 years | +1.4% | -12.1% | +0.1% |
| 5 y5 years | -9.8% | -41.9% | +9.0% |
INFI EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -270.5% | -109.1% | -257.3% |
Infinity Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$9.80 M(-10.0%) | -$40.34 M(-4.8%) |
| Mar 2023 | - | -$10.89 M(+20.0%) | -$42.36 M(-3.1%) |
| Dec 2022 | -$43.73 M(-2.0%) | -$9.08 M(-14.0%) | -$43.73 M(-5.2%) |
| Sept 2022 | - | -$10.56 M(-10.7%) | -$46.14 M(+0.0%) |
| June 2022 | - | -$11.82 M(-3.7%) | -$46.12 M(+1.6%) |
| Mar 2022 | - | -$12.27 M(+6.8%) | -$45.41 M(+1.8%) |
| Dec 2021 | -$44.60 M(+18.7%) | -$11.49 M(+8.9%) | -$44.60 M(+3.8%) |
| Sept 2021 | - | -$10.55 M(-5.0%) | -$42.95 M(+4.3%) |
| June 2021 | - | -$11.10 M(-3.1%) | -$41.19 M(+6.1%) |
| Mar 2021 | - | -$11.46 M(+16.5%) | -$38.84 M(+3.4%) |
| Dec 2020 | -$37.56 M(-15.3%) | -$9.84 M(+12.0%) | -$37.56 M(-3.5%) |
| Sept 2020 | - | -$8.79 M(+0.4%) | -$38.93 M(-3.5%) |
| June 2020 | - | -$8.75 M(-14.2%) | -$40.37 M(-1.6%) |
| Mar 2020 | - | -$10.19 M(-9.0%) | -$41.04 M(-7.4%) |
| Dec 2019 | -$44.33 M(+304.1%) | -$11.21 M(+9.7%) | -$44.33 M(+7.3%) |
| Sept 2019 | - | -$10.22 M(+8.5%) | -$41.31 M(+133.8%) |
| June 2019 | - | -$9.42 M(-30.1%) | -$17.67 M(+16.6%) |
| Mar 2019 | - | -$13.48 M(+64.6%) | -$15.16 M(+38.2%) |
| Dec 2018 | -$10.97 M(-72.5%) | -$8.19 M(-161.0%) | -$10.97 M(+3.4%) |
| Sept 2018 | - | $13.43 M(-294.3%) | -$10.61 M(-65.3%) |
| June 2018 | - | -$6.91 M(-25.7%) | -$30.59 M(-22.8%) |
| Mar 2018 | - | -$9.29 M(+18.8%) | -$39.64 M(-0.5%) |
| Dec 2017 | -$39.83 M(+56.4%) | -$7.83 M(+19.4%) | -$39.83 M(-25.9%) |
| Sept 2017 | - | -$6.56 M(-58.9%) | -$53.77 M(-17.6%) |
| June 2017 | - | -$15.96 M(+68.4%) | -$65.23 M(-1481.1%) |
| Mar 2017 | - | -$9.48 M(-56.5%) | $4.72 M(-118.6%) |
| Dec 2016 | -$25.46 M(-79.5%) | -$21.77 M(+20.9%) | -$25.46 M(-39.3%) |
| Sept 2016 | - | -$18.01 M(-133.4%) | -$41.97 M(-310.3%) |
| June 2016 | - | $53.99 M(-236.1%) | $19.96 M(-127.8%) |
| Mar 2016 | - | -$39.66 M(+3.6%) | -$71.74 M(-42.3%) |
| Dec 2015 | -$124.38 M(+2040.4%) | -$38.29 M(-187.2%) | -$124.38 M(-0.3%) |
| Sept 2015 | - | $43.92 M(-216.5%) | -$124.81 M(+106.2%) |
| June 2015 | - | -$37.72 M(-59.1%) | -$60.53 M(+5.4%) |
| Mar 2015 | - | -$92.30 M(+138.4%) | -$57.45 M(+888.7%) |
| Dec 2014 | -$5.81 M(-95.4%) | -$38.72 M(-135.8%) | -$5.81 M(+1264.1%) |
| Sept 2014 | - | $108.20 M(-412.4%) | -$426.00 K(-99.7%) |
| June 2014 | - | -$34.63 M(-14.8%) | -$142.10 M(+1.8%) |
| Mar 2014 | - | -$40.66 M(+22.0%) | -$139.63 M(+10.9%) |
| Dec 2013 | -$125.85 M(+149.6%) | -$33.33 M(-0.4%) | -$125.85 M(-9.5%) |
| Sept 2013 | - | -$33.47 M(+4.1%) | -$139.12 M(+61.2%) |
| June 2013 | - | -$32.16 M(+19.6%) | -$86.31 M(+27.5%) |
| Mar 2013 | - | -$26.88 M(-42.3%) | -$67.70 M(+34.3%) |
| Dec 2012 | -$50.41 M(+39.6%) | -$46.60 M(-340.9%) | -$50.41 M(+198.9%) |
| Sept 2012 | - | $19.34 M(-242.6%) | -$16.87 M(-64.3%) |
| June 2012 | - | -$13.56 M(+41.3%) | -$47.25 M(+6.2%) |
| Mar 2012 | - | -$9.60 M(-26.5%) | -$44.47 M(+22.6%) |
| Dec 2011 | -$36.10 M | -$13.05 M(+18.2%) | -$36.27 M(+0.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | -$11.04 M(+2.4%) | -$36.18 M(-20.9%) |
| June 2011 | - | -$10.78 M(+676.2%) | -$45.71 M(+14.4%) |
| Mar 2011 | - | -$1.39 M(-89.3%) | -$39.94 M(-12.8%) |
| Dec 2010 | -$45.59 M(+61.9%) | -$12.97 M(-37.0%) | -$45.82 M(+17.9%) |
| Sept 2010 | - | -$20.57 M(+310.5%) | -$38.87 M(+46.0%) |
| June 2010 | - | -$5.01 M(-31.1%) | -$26.62 M(-22.4%) |
| Mar 2010 | - | -$7.27 M(+20.9%) | -$34.31 M(-21.5%) |
| Dec 2009 | -$28.15 M(-209.8%) | -$6.01 M(-27.8%) | -$43.68 M(-454.4%) |
| Sept 2009 | - | -$8.33 M(-34.4%) | $12.33 M(+51.7%) |
| June 2009 | - | -$12.70 M(-23.7%) | $8.12 M(-13.2%) |
| Mar 2009 | - | -$16.65 M(-133.3%) | $9.36 M(-63.5%) |
| Dec 2008 | $25.65 M(-225.2%) | $50.00 M(-499.0%) | $25.65 M(-177.6%) |
| Sept 2008 | - | -$12.53 M(+9.3%) | -$33.03 M(+41.7%) |
| June 2008 | - | -$11.46 M(+3076.6%) | -$23.31 M(+38.0%) |
| Mar 2008 | - | -$360.80 K(-95.8%) | -$16.90 M(-17.5%) |
| Dec 2007 | -$20.48 M(-11.2%) | -$8.68 M(+208.7%) | -$20.48 M(+40.2%) |
| Sept 2007 | - | -$2.81 M(-44.3%) | -$14.61 M(-5.8%) |
| June 2007 | - | -$5.05 M(+27.9%) | -$15.50 M(-8.7%) |
| Mar 2007 | - | -$3.95 M(+40.6%) | -$16.98 M(-26.4%) |
| Dec 2006 | -$23.08 M(-29.2%) | -$2.81 M(-24.2%) | -$23.08 M(-21.3%) |
| Sept 2006 | - | -$3.70 M(-43.2%) | -$29.30 M(-16.7%) |
| June 2006 | - | -$6.53 M(-35.0%) | -$35.18 M(+12.5%) |
| Mar 2006 | - | -$10.04 M(+11.1%) | -$31.27 M(+28.7%) |
| Dec 2005 | -$32.60 M(+9.3%) | -$9.03 M(-5.7%) | -$24.29 M(-51.9%) |
| Sept 2005 | - | -$9.58 M(+265.7%) | -$50.54 M(+29.8%) |
| June 2005 | - | -$2.62 M(-14.5%) | -$38.93 M(+13.9%) |
| Mar 2005 | - | -$3.06 M(-91.3%) | -$34.19 M(+18.1%) |
| Dec 2004 | -$29.82 M(-539.2%) | -$35.28 M(-1835.5%) | -$28.96 M(-418.4%) |
| Sept 2004 | - | $2.03 M(-4.3%) | $9.09 M(+0.3%) |
| June 2004 | - | $2.12 M(-2.0%) | $9.07 M(+15.4%) |
| Mar 2004 | - | $2.17 M(-21.8%) | $7.86 M(+15.2%) |
| Dec 2003 | $6.79 M(-192.5%) | $2.77 M(+38.0%) | $6.82 M(-448.0%) |
| Sept 2003 | - | $2.01 M(+120.1%) | -$1.96 M(-51.6%) |
| June 2003 | - | $912.00 K(-19.2%) | -$4.05 M(-36.1%) |
| Mar 2003 | - | $1.13 M(-118.8%) | -$6.33 M(-13.7%) |
| Dec 2002 | -$7.34 M(+258.0%) | -$6.01 M(+7325.5%) | -$7.34 M(+29.5%) |
| Sept 2002 | - | -$80.90 K(-94.1%) | -$5.67 M(-41.4%) |
| June 2002 | - | -$1.37 M(-1226.4%) | -$9.67 M(+42.4%) |
| Mar 2002 | - | $122.00 K(-102.8%) | -$6.79 M(+11.3%) |
| Dec 2001 | -$2.05 M(-122.7%) | -$4.34 M(+6.2%) | -$6.10 M(-193.4%) |
| Sept 2001 | - | -$4.08 M(-370.8%) | $6.53 M(-43.9%) |
| June 2001 | - | $1.51 M(+85.9%) | $11.65 M(-0.4%) |
| Mar 2001 | - | $810.90 K(-90.2%) | $11.69 M(+3.3%) |
| Dec 2000 | $9.02 M(-425.0%) | $8.30 M(+702.7%) | $11.32 M(+274.9%) |
| Sept 2000 | - | $1.03 M(-33.3%) | $3.02 M(+52.1%) |
| June 2000 | - | $1.55 M(+256.5%) | $1.98 M(+356.5%) |
| Mar 2000 | - | $434.70 K | $434.70 K |
| Dec 1999 | -$2.78 M | - | - |
FAQ
- What is Infinity Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals annual EBITDA year-on-year change?
- What is Infinity Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Infinity Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals TTM EBITDA year-on-year change?
What is Infinity Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of INFI is -$43.73 M
What is the all time high annual EBITDA for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $25.65 M
What is Infinity Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, INFI annual earnings before interest, taxes, depreciation & amortization has changed by +$871.00 K (+1.95%)
What is Infinity Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of INFI is -$9.80 M
What is the all time high quarterly EBITDA for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $108.20 M
What is Infinity Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, INFI quarterly earnings before interest, taxes, depreciation & amortization has changed by +$2.02 M (+17.05%)
What is Infinity Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of INFI is -$40.34 M
What is the all time high TTM EBITDA for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $25.65 M
What is Infinity Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, INFI TTM earnings before interest, taxes, depreciation & amortization has changed by +$5.78 M (+12.54%)